

Evaluation Report

Final Decision: Reconsider for Evaluation after Modifications and Clarifications

Article No.: 101466-PJBS-ANSI

Article Type: Research Article

Figures Available: 1 Figures Cited: 1

Table Available: 1 Tables cited: 1

Manuscript falls in the scope of the journal? **Yes** No

My observations/comments about this article are:

No.	Part	• Comments	Author Response
1	Cover letter	• Overall Ok	√
2	Write up	• Author is advised to correct the typographical mistakes. Typographical Mistakes might affect the efficiency of paper. e.g reliabilitystatistical (space in words)	The typing errors have been corrected
3	Title	• Overall Ok	√
4	Running Title	• Running title of the study is missing. • Author has to provide a running title of 7-9 words besides the main title in manuscript and it must be the punch line of main title.	Running title has been included
5	Author's Information	• Overall Ok	√
6	Author's Contribution	• Overall Ok	√
7	Abstract	• Overall Ok	√
8	Keywords	• Provide at least 5 to 6 key words. Author is advised to either use the suggested keywords (given below) or write the keywords according to his own choice.	Keywords have been provided accordingly
9	Introduction	• Overall Ok	√

10	Materials and Methods	• Overall Ok	√
11	Results	• Overall Ok	√
12	Figures	• Overall Ok	√
13	Tables	• Overall Ok	√
14	Discussion	• Overall Ok	√
15	Conclusion	• Overall Ok	√
16	Acknowledgement	• Overall Ok	√
17	Significance Statement	• Overall Ok	√
18	References	• Reference no. 40 to 78 is not cited in the manuscript. Author is advised to clarify this statement.	The mentioned references have been removed

Guidelines to attend the Comments:

- Author is requested to please highlight the amended portion in the manuscript. It will be more helpful for us in cross checking of suggested modifications.
- Please give your response in the Evaluation report as well under the column “**Author Response**” for all the parts of the manuscript.
- Incorporate all the recommended modifications in their respective sections throughout the manuscript.

Plagiarism checked

[101466-PJBS-ANSI](#)

Research Article

**Antimicrobial Activities of *Rhopalaea*-Associated Fungus *Aspergillus flavus*
Strain MFABU9**

¹Deiske A. Sumilat, ¹Elvy L. Ginting, ²Gracia A. V. Pollo, ³Ahmad A. Adam ⁴Trina E. Tallei

¹Marine Science Study Program, Faculty of Fisheries and Marine Science, Sam Ratulangi University, Manado, Indonesia.

²Biology Master Study Program, Faculty of Mathematics and Natural Sciences, Gadjah Mada University, Yogyakarta, Indonesia

³Dental Profession Program, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia.

⁴Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia.

Corresponding Author name: Deiske A. Sumilat

Corresponding Email: deiske.sumilat@unsrat.ac.id

Marine Science Study Program, Faculty of Fisheries and Marine Science, Sam Ratulangi University, Manado, Indonesia.

LiveDNA: 62.32242

Running Title: **Antimicrobial Activities of *Rhopalaea*-Associated Fungus *Aspergillus flavus***

Authors' contribution

Name of the author and e-mail ID	Types of contribution
----------------------------------	-----------------------

Commented [WU1]: •Running title of the study is missing. Author has to provide a running title of 7-9 words besides the main title in manuscript and it must be the punch line of main title.

Deiske A. Sumilat Email: deiske.sumilat@unsrat.ac.id	Principal investigator/First author/Corresponding author: Planning and contribution to conception or design of research, data analysis, interpretation.
Elvy L. Ginting Email: like.ginting@unsrat.ac.id	Co-author: Data analysis and interpretation, manuscript writing, and the critical revision of the manuscript.
Gracia A. V. Pollo Email: graciapollo@mail.ugm.ac.id	Co-author: Data collection, data analysis, interpretation
Ahmad A. Adam Email: ahmad_adam@ymail.com	Co-author: Data collection, data analysis, interpretation
Trina Ekawati Tallei Email: trina_tallei@unsrat.ac.id	Co-author: Data analysis and interpretation, manuscript writing, critical revision of the manuscript, and finalization of the manuscript.

Conflict of interest

We have no conflict of interest to declare.

Abstract

Background and Objective: *Rhopalaea* is a genus of ascidian belonging to the family Diazonidae. Ascidians provide niches for various microorganisms including fungi. This present study describes the potential new source for natural bioactive compounds from *Rhopalaea*-associated fungi obtained from Bunaken marine park.

Materials and Methods: As part of an on-going research program to explore the chemical diversity of marine derived fungi, we performed an antimicrobial bioactivity-guided screening of EtOAc extracts of the fungi isolated from ascidian *Rhopalaea* sp.

Results: The study confirms that the ascidian obtained from Bunaken marine park was *Rhopalaea* sp. The fungus isolated from the ascidian was *Aspergillus flavus* which showed antimicrobial activity against bacteria *Escherichia coli*, *Staphylococcus aureus*, *Aeromonas hydrophila*, and antifungal against the human pathogenic fungus *Candida albicans*.

Conclusion: *Aspergillus flavus* isolated from ascidian *Rhopalaea* sp. has the potential as antibacterial and antifungal.

Keywords:

ascidian, antimicrobial, *Aspergillus*, bioactive compound, marine derived-fungus, *Rhopalaea*

Introduction

Marine-derived fungi are well recognised as a source of various novel metabolites, many of which possess valuable biological properties^{1,2} and pharmacological properties³. Marine-derived fungi which found in algae⁴, mangrove⁵, ascidians⁶, and sponges⁷ were shown to have antibacterial and anticancer activities.

Ascidians are found abundantly all over the world. They mostly live in shallow water with salinities over 2.5%⁸. However, they also can be found in the depths of the sea. Ascidian is a marine invertebrate animal and a member of the subphylum Tunicata. It productively produce a wide variety of secondary metabolites which are biologically and pharmacologically active⁹. These compounds have properties such as antibacterial¹⁰ and anticancer¹¹ activities which make them candidates for potential new drugs.

Correlations between ascidian microorganisms and ascidian metabolites are also being investigated, while the structures and synthetic pathways of a growing number of relevant compounds have been identified¹². Many of these metabolites are produced by the fungi isolated from ascidian^{9, 13, 14}. A number of new metabolites have been reported describing the fungal

association with ascidians. As an example, Indonesian ascidian produced *Penicillium verrucosum* which inhibited the activity of PTP 1B¹⁵ as well as *P. albobiverticillium*¹⁶. Menezes et al.¹⁷ analyzed in detail about fungal diversity in *Didemnum* spp.

Some compounds have been isolated from marine ascidians-derived fungi, which are taxonomically similar or identical to terrestrial fungi, such as *Aspergillus*¹⁸. The genus *Aspergillus*, which includes approximately 200 species, has been well studied and shown to produce many new metabolites¹⁹. Various fungal strains which predominated by *Aspergillus* and *Cladosporium* were have been isolated from various Australian coral reefs²⁰. An ascidian-derived fungus *Aspergillus* sp. KMM 4676 exhibited cytotoxic activity as hormone therapy-sensitive human prostate cancer cells²¹. *Aspergillus candidus* isolated from colonial ascidian had a cytotoxic activity ~~toxic~~ against hormone-sensitive line LNCaP²². Various kind of marine fungal strains has been reported to produce many kind of novel antimicrobial compounds. These compounds belong to alkaloids, macrolides, terpenoids, peptide derivatives as well as other structure types²³.

Bunaken marine park in North Sulawesi (Indonesia) has been known for its various types of ascidians, among other is *Rhopalaea* sp. This type of ascidian is rarely investigated in association with the fungi and their antibacterial activities. In this present study, *Rhopalaea* sp. from Bunaken marine park was studied to observe the possibility of its associated fungi for antibacterial activity.

Materials and Methods

Sample preparation

Ascidian *Rhopalaea* sp. (Figure 1) was collected at the Bunaken marine park in North Sulawesi, Indonesia, in March 2019. The ascidian was rinsed with sterilized sea water and immersed in ethanol 70% for 1 minute, then kept in the bottle vial and stored in the cool box and transported to the laboratory for further observation²⁴.

Isolation of ascidian-derived fungi from Rhopalaea sp.

A small piece of the sample was cut into cubes, washed with sterilized seawater, and grown on PDA plate (BD, Franklin Lakes, NJ, theUSA). The plate was incubated at 25°C for a week. The different appearing fungal colonies surrounding the samples that have different characteristics were isolated and grown on PDA. The isolation process was conducted for another round to obtain a pure single colony²⁴. One pure isolate designated as MFABU9 was chosen and grown on PDA. Afterwards, the isolate was inoculated into a 100-mL Erlenmeyer flask containing 50 mL sterilized sea water and 50 mg sterilized rice as rice medium for 14 days.

EtOAc Extraction of MFABU9 Isolate

The 100 g of rice medium containing the selected growing fungus was extracted with EtOAc for 24 hours. To complete the extraction process, the rice was incubated in 200 ml of EtOAc for 3 days at 25°C with constant shaking. The solvent was filtered using Whatman No.1 filter paper. The first filtrate was set aside in one clean Erlenmeyer, and the remaining debris was soaked in 200 ml of EtOAc for 3 days at 25°C with constant shaking. The second and third filtrates were obtained using the same process. All of the filtrates were then combined and concentrated using a vacuum rotary evaporator at 40°C to obtain concentrated extract. The concentrated extract was then evaporated in the incubator to obtain a dry extract. The dry extract was weighted and stored in 20°C until used.

Screening for antimicrobial activity

The indicator pathogens used were bacterial strains of *E. coli*, *S. aureus*, *Aeromonas hydrophila*, *Salmonella* sp., *Edwardsiella tarda* and *C. albicans*. Each of the bacterial inoculum of *E. coli*, *S. aureus*, and *A. Hydrophila* were cultured in liquid media B1 (peptone, meat extract, NaCl

and aquadest) for 1 x 24 hours, while *Salmonella sp.* and *E. tarda* were cultured in TSA media. Anti-bacterial assay was carried out by the paper disc method using agar diffusion Kirby-Bauer methods, following the guidelines of Clinical and Laboratory Standard Institute (CLSI)²⁵.

The EtOAc extract of isolate MFABU9 was examined for the inhibitory activities against the indicator pathogenic bacteria and fungus with the concentrations of 20 µg / disk. The pathogenic bacteria were grown in Nutrient Agar (NA), while the indicator fungus was grown in Saboraud Dextrose Agar (SDA). Chloramphenicol was used as positive control for bacteria and Ketoconazole for fungus. For negative control, 40% CH₃OH was used. The plates were incubated at 37°C and the inhibitory activities were measured after 48 hours of incubation. The results were interpreted by measuring the diameter of the inhibition zone using a caliper. The inhibition zone is a measure of the effectiveness of an active compound. Generally, a larger zone of inhibition means that the antimicrobial is more potent.

Molecular identification of isolate MFABU9

DNA extraction of the fungal isolate was carried out using Quick-DNA Fungal/Bacterial Miniprep Kit (Zymo Research, D6005). The ITS (internal transcribed spacer) region was amplified using with primer pair ITS1 (F 5'- TCC GTA GGT GAA CCTGCG G-3') and ITS4 (R 5'- TCC TCC GCT TAT TGA TATGC-3') in the MyTaq HS Red Mix (Bioline, BIO-25047). The following PCR amplification conditions were one cycle of initial denaturation at 95°C for 5 minutes, followed by 35 cycles with a step of denaturation at 95°C for 30 seconds, step annealing at 55°C for 1 minute, and step extension at 72°C for 1 minute, followed by one cycle at 72°C for 6 minutes.

PCR products were purified using Zymoclean™ Gel DNA Recovery Kit (Zymo Research, D4001) and sent to the sequencing service provider. ~~IBASE in Malaysia~~. The sequencing result was processed following the procedure performed by Tallei et al.²⁶ and subjected to BLAST (Basic

Local Alignment Search Tool) search at NCBI (National Center for Biotechnology Information <https://www.ncbi.nlm.nih.gov/>), ISHAM (International Society for Human & Animal Mycology <https://www.isham.org/>), and BOLD (Barcode of Life Data System <http://www.boldsystems.org/>), and MycoBank (<http://mycobank.org>) for species identification.

Results and Discussion

The fungal extract of isolate MFABU9 only showed antibacterial activity against *E. coli*, *S. aureus*, *A. hydrophila*, and antifungal activity against *C. albicans* ~~seen in~~ (Table 1). The extract, however, failed to suppress the growth of *E. tarda* and *Salmonella* sp. The isolate MFABU9 was molecularly identified as *Aspergillus flavus*, hence it is called *A. flavus* strain MFABU9. Inhibitory activity could be defined by the diameter of inhibition zones. Inhibitory activity is defined as weak if the diameter is less than 10 mm. Inhibitory activity is defined as intermediate if the diameter ranges between 10 to 15 mm. Meanwhile, inhibitory activity is defined as strong if the diameter is more than 16 mm. According to this, the extract of *A. flavus* strain MFABU9 showed a weak inhibitory activity against *S. aureus* and *C. albicans*, and intermediate inhibitory activity against *E. coli* and *A. hydrophila*.

~~Based on the molecular identification, ascidian-derived fungal strain MFABU9 was identified as *Aspergillus flavus*, a saprotrophic and cosmopolitan fungus.~~ Only a little information about *A. flavus* isolated from ascidian that has been reported. Marine-derived *A. flavus* produced various kinds of secondary metabolites including mutagenic mycotoxins and other bioactive compounds²⁷. Ivanets et al.²¹ were able to isolate asperindoles A–D and a p-terphenyl derivative from the ascidian-derived fungus *Aspergillus* sp. KMM 4676 which inhibited the growth of hormone therapy-resistant PC-3 and 22Rv1 and hormone therapy-sensitive human prostate cancer cells.

Some marine algal-derived *A. flavus* has been reported to produce bioactive compounds. A cerebroside, an antibacterial cerebroside derivative isolated from *A. flavus* had antibacterial activity against *Staphylococcus aureus*, methicillin-resistant *S. aureus*, and multidrug-resistant ~~to~~ *S. aureus*²⁸. Citrinadins A and B had been isolated from *A. flavus* which is associated with a green alga *Enteromorpha tubulosa*. This compound was cytotoxic to several tumor cell lines HL-60, MOLT-4, A-549, and BEL-7402²⁹.

Ascidian has become a source of so many types of secondary metabolites. The resulting metabolites are used for physiological functions and specifically for defence mechanism against predators. Secondary metabolites which are synthesized by ascidians are not only synthesized by ascidians themselves, but also can be synthesized by the associated-microorganisms³⁰. Fungi are one of the microorganisms associated with ascidians. Most of the fungi can be found in the ascidian's tunic and several others can be found in the inside of the ascidian³¹.

Some types of fungi show specific relationships with ascidians. Fungi are involved in the ascidian's synthesis of bioactive secondary metabolites. However, the relationship between most fungi and specific ascidians is unclear. This indicates that the functional interactions between ascidians and fungi, especially in the interaction of *Rhopalaea* sp. and *A. flavus*, are still unclear³².

Aspergillus is a genus of filamentous fungi. It has been widely used as a source of medicines³². Several species of the genus *Aspergillus* could produce various types of compounds. Some of the compounds were aminobenzoic peptide secoclavastide B, clavatoic acid derivative 5-acetyl-2,4-dihydroxy-3-methyl-benzoic acid³³, clavastide B³⁴, demethylsiderin, 3,7-dihydroxy-4-methylcoumarin and demethylkolanin³⁵.

The fungal species of the genus *Aspergillus* which could be found in waters and associated with marine organisms, have many metabolites that have been proven to have the antibacterial and antifungal ability³⁶. The analysis of *A. flavus* extract showed that this fungus has antibacterial

activity against *S. aureus*, *E. coli* and *A. hydrophila* and antifungal against *C. albicans*. This can be caused by the role of secondary metabolites of *A. flavus*. However, these antibacterial and antifungal activities did not only depend on certain types of synthesized compounds. These activities may be influenced by various metabolite compounds that play a synergistic or antagonistic role that support these activities³⁷. This is because the responses showed by the extract not only could be seen from the response that not only arises against bacteria and fungi (*C. albicans*), but also in its response to against Gram-positive (*S. aureus*) and Gram-negative bacteria (*E. coli* and *A. hydrophila*).

Besides the synergistic and antagonistic roles, specific types of synthesized compounds may also perform different antibacterial mode of actions to specific types of bacteria. It is because of different types of bacterial cells, which are gram positive and gram negative bacteria, could may only be affected by the specific mode of action³⁸. It can be implied that *A. flavus* could synthesized may synthesize compounds with antibacterial activity against *S. aureus*, *E. coli* and *A. hydrophila* with specific reaction and mode of action.

Conclusion

The results obtained from the present study confirmed that *A. flavus* strain MFABU9 isolated from ascidian *Rhopalaea* sp. showed weak to intermediate inhibitory activities against selected indicator pathogenic microorganisms. Further studies are needed to be conducted to isolate each of bioactive compounds from this strain and tested for their antibacterial and anticancer activities. The data obtained in this study have opened of the importance of a preliminary screening study. The molecular docking can be conducted after bioactive compounds from this strain have been elucidated.

Significance statement

This study discovered that fungus *A. flavus* isolated from ascidian *Rhopalaea* sp. obtained from the Bunaken marine park showed antibacterial activities against *E. coli*, *S. aureus*, and *A. hydrophila* and antifungal activity against *C. albicans*. However, it is advisable to explore further the bioactive compounds of this fungus which can be used as antimicrobial agents.

Acknowledgment

This work was financed by the Directorate of Research and Community Service, Ministry of Research, Technology, and Higher Education, Republic of Indonesia, through Basic Research Sceme fiscal year 2019 (Grant Number:127/UN12.13/LT/2019).

Table 1: Antimicrobial assay of *A. flavus* strain MFABU9 extract

Indicator Microbes	Inhibition Zone (mm)
	Indicator Bacteria
<i>Escherichia coli</i>	10.75
<i>Staphylococcus aureus</i>	9
<i>Edwardsiellatarda</i>	-
<i>Salmonella</i> sp.	-
<i>Aeromonashydrophila</i>	11.45
Control + (Chloramphenicol)	25
Control -	-
	Indicator Fungus
<i>Candida albicans</i>	9.5
Control + (Ketoconazole)	25
Control -	-



Figure 1. Ascidian *Rhopalaea* sp. collected at Bunaken marine park in North Sulawesi, Indonesia

References

1. Deshmukh SK, Prakash V, Ranjan N. Marine fungi: a source of potential anticancer compounds. *Front. Microb.* 2018; 8: 2536.
2. Butler MS, Robertson AA, Cooper MA. Natural product and natural product derived drugs in clinical trials. *Nat. Prod. Rep.* 2014; 31: 1612-1661.
3. Ebel R. Terpenes from marine-derived fungi. *Mar. Drugs* 2010; 8(8): 2340-2368.
4. Handayani D, Ananda N, Artasasta MA, Ruslan R, Fadriyanti O, Tallei TE. Antimicrobial activity screening of endophytic fungi extracts isolated from brown algae *Padina* sp. *J. App. Pharm. Sci.* 2019; 9(03): 009-013.
5. Handayani D, Sandrawati N, Ruslan R, Nestianda O, Fajrina A, Tallei TE. Cytotoxic and antimicrobial activities of ethyl acetate extract of mangrove plant *Scyphiphora hydrophyllacea* C. F. Gaertn-Associated fungi. *J. App. Pharm. Sci.* 2019; 9(06): 075-079.
6. Chen L, Hu JS, Xu JL, Shao CL, Wang GY. Biological and chemical diversity of ascidian-associated microorganisms. *Mar. Drugs* 2018; 16(10): 362.
7. Handayani D, Artasasta MA. Antibacterial and cytotoxic activities screening of symbiotic fungi extract isolated from marine sponge *Neopetrosia chaliniformis* AR-01. *J. App. Pharm. Sci.* 2017; 7(05): 066-069.
8. Saha A, Yadav R, Rajendran N. Biomaterials from sponges, ascidians and other marine organisms. *Int. J. Pharm. Sci. Rev. Res.* 2014; 27(2): 100-109.
9. Watters DJ. Ascidian toxins with potential for drug development. *Mar. Drugs* 2018; 16(5): 162.
10. Adam AA, Posangi J, Tumewu E, Tallei TE. Aktivitas antibakteri ekstrak kasar tunikata *Polycarpa aurata* terhadap *Streptococcus mutans*. *Dentire* 2014; 3(2): 118 - 122
11. Chandramathi V, Thilaga RD, Sivakumar M. Antibacterial activity of methanol extract of colonial ascidian *Distaplia nathensis*. *Global J. Biotech. Biochem.* 2011; 4: 183-185.
12. Chen L, Fu C, Wang G. Microbial diversity associated with ascidians: a review of research methods and application. *Symbiosis* 2017; 17: 19-26.
13. Sumilat DA, Wewengkang DS, Rotinsulu H, Yamazaki H, Oda T, Ukai K, Namikoshi M. Bioactivity of extracts from ascidians collected in North Sulawesi as seeds of marine-derived drugs. *AAAL Bioflux* 2018; 11(2): 516-524.

14. Sumilat DA, Rimper JRTSL, Opa ET, Kurnia D. The potential of marine ascidians as sources of natural antioxidant and antibacterial agent from Manado, North Sulawesi. *AAFL Bioflux* 2019; 12(1): 373 – 377.
15. Yamazaki H, Nakayama W, Takahashi O, Kirikoshi R, Izumikawa Y, Iwazaki K, *et al.* Verruculides A and B, two new protein tyrosine phosphatase 1B inhibitors from an Indonesian ascidian-derived *Penicillium verruculosum*. *Bioorg. Med. Chem. Lett.* 2015; 25(16): 3087–3090.
16. Sumilat DA, Yamazaki H, Endo K, Rotinsulu H, Wewengkang DS, Ukai K, Namikoshi M. A new biphenyl ether derivative produced by Indonesian ascidian-derived *Penicillium albobiverticillium*. *J. Nat. Med.* 2017; 71(4): 776–779.
17. Menezes CBA, Bonugli-Santos RC, Miqueletto PB, Passarini MRZ, Silva CHD, Justo MR, *et al.* Microbial diversity associated with algae, ascidians and sponges from the north coast of São Paulo state, Brazil. *Microbiol. Res.* 2010; 165: 466–482.
18. Namikoshi M, Xu JZ. Filamentous Fungi in the Marine Environment. *In* *Fungi from Different Environments*, Misra JK, Deshmukh SK (eds.). Taylor and Francis, London 2009, pp. 81-112.
19. Carroll AR, Copp, BR, Davis RA, Keyzers RA, Prinsep, MR. Marine natural products. *Nat. Prod. Rep.* 2019; 36: 122-173.
20. Morrison-Gardiner S. Dominant fungi from Australian coral reefs. *Fungal Divers.* 2002; 9: 105–121.
21. Ivanets EV, Yurchenko AN, Smetanina OF, Rasin AB, Zhuravleva OI, Pivkin MV, *et al.* Asperindoles A–D and a p-terphenyl derivative from the ascidian-derived fungus *Aspergillus sp.* KMM 4676. *Mar. Drugs* 2018; 16: 232-244.
22. Yurchenko AN, Ivanets EV, Smetanina OF, Pivkin MV, Dyshlovoi SA, Amsberg G, Afiyatullof S. Metabolites of the marine fungus *Aspergillus candidus* KMM 4676 associated with a kuril colonial ascidian. *Chem. Nat. Compd.* 2017; 53(4): 747-749.
23. Zhang Y, Mu J, Feng Y, Kang Y, Zhang J, Gu PJ, *et al.* broad-spectrum antimicrobial epiphytic and endophytic fungi from marine organisms: isolation, bioassay and taxonomy. *Mar. Drugs* 2009; 7: 97-112
24. Kjer J, Debbab A, Aly AH, Proksch P. Methods for isolation of marine-derived endophytic fungi and their bioactive secondary products. *Nat. Protoc.* 2010; 5(3): 479–490.
25. Clinical and Laboratory Standard Institute (CLSI) (2019); Available from <https://clsi.org/> [accessed 12 November 2019].
26. Tallei TE, Kolondam BJ. DNA barcoding of Sangihe nutmeg (*Myristica fragrans*) using matK gene. *Hayati J. Biosci.* 2015; 22(1): 41-47; Doi: 10.4308/hjb.22.1.4
27. Lamboni Y, Nielsen KF, Linnemann AR, Gezgin Y, Hell K, Nout MJR, *et al.* Diversity in secondary metabolites including mycotoxins from strains of *Aspergillus* Section Nigri isolated from raw cashew nuts from Benin, West Africa. *PLoS ONE* 2016; 11(10): e0164310. Doi:10.1371/journal.pone.0164310
28. Yang GH, Sandjo L, Yun K, Leutou AS, Kim GD, Choi HD, *et al.* Flavusides A and B, antibacterial cerebroside from the marine-derived fungus *Aspergillus flavus*. *Chem. Pharm. Bull.* 2011; 59: 1174-1177.
29. Lin AQ, Du L, Fang YC, Wang FZ, Zhu TJ, Gu QQ, Zhu WM. Iso- α -Cyclopia-zonic acid, a new natural product isolated from the marine-derived fungus *Aspergillus flavus* C–F. *Chem. Nat. Compd.* 2009; 45: 677-680.
30. Karim F, Putra MY, Hadi TA, Abrar M. Antimicrobial and cytotoxic properties of the Ascidians *Lissoclinum patella*, *Oxycoryna fascicularis*, *Didemnummolle* and *Botryllus chlosseri*. *Pharm. Sci. Res.* 2018; 5(2): 65-71.

31. López-Legentil S, Erwin PM, Turon M, Yarden O. Diversity of fungi isolated from three temperate ascidians. *Symbiosis* 2015; 66(2): 99-106.
32. Sanchez JF, Somoza AD, Keller NP, Wang CC. Advances in *Aspergillus* secondary metabolite research in the post-genomic era. *Nat. Prod. Rep.* 2012; 29(3):351-371.
33. Song Q, Li XM, Hu XY, Li X, Chi LP, Li HL, Wang BG. 2019. Antibacterial metabolites from ascidian-derived fungus *Aspergillus clavatus* AS-107. *Phytochem. Lett.* 2019; 34: 30-34.
34. Jiang W, Ye PP, Chen CTA., Wang KW, Liu PY, He S, et al. Two novel hepato-cellular carcinoma cycle inhibitory cyclodepsi-peptides from a hydrothermal vent crab-associated fungus *Aspergillus clavatus* C2WU. *Mar. Drugs* 2013; 11: 4761–4772.
35. Hüttel W, Müller M. Regio- and stereoselective intermolecular oxidative phenol coupling in kotanin biosynthesis by *Aspergillus niger*. *Chem. Bio. Chem.* 2007; 8: 521-529.
36. Bajpai VK. Antimicrobial secondary metabolites from Marine Fungi: A mini review. *Indian J. Geo-Mar. Sci.* 2016; 45(9): 1067-1075.
37. Ruangamnart A, Buranaphalin S, Temsiririrkkul R, Chuakul W, Pratuangdejkul J. Chemical compositions and antibacterial activity of essential oil from dill fruits (*Anethum graveolens* L.) cultivated in Thailand. *Mahidol. Univ. J. Pharm. Sci.* 2015; 42(3): 135-143.
38. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: a guide for clinicians. *J. Anaesthesiol. Clin. Pharmacol.* 2017; 33: 300-305. |

Commented [WU2]: Reference no. 40 to 78 are not cited in the manuscript. Author is advised to clarify this statement.